Open Menu Close Menu Open Search Close Search

Pragmatic Trials of Managing Multimorbidity in Alzheimer’s Disease (R61/R33 Clinical Trial Required)
(RFA-AG-20-029)

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). The research will: (1) be designed to address practical comparative questions faced by AD/ADRD patients and clinicians, (2) include broad and diverse populations, and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare systems for rapid translation. This FOA will support pilot research to test the feasibility of implementing care interventions (R61 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials. The transition from the R61 phase to the R33 phase of the award will be administratively reviewed and determined by successful completion of the Go/No-Go Criteria that are specified for the R61 phase.

Application Due Date(s): February 3, 2020